NASDAQ:RDUS Radius Health Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Radius Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $10.44 -0.06 (-0.57%) (As of 06/29/2022 11:57 AM ET) Add Compare Share Today's Range$10.25▼$10.4850-Day Range$5.53▼$10.8452-Week Range$4.97▼$23.00Volume20,536 shsAverage Volume1.09 million shsMarket Capitalization$496.94 millionP/E RatioN/ADividend YieldN/APrice Target$8.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RDUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter. Email Address RDUS Stock Forecast (MarketRank)Overall MarketRank™1.54 out of 5 starsMedical Sector1026th out of 1,433 stocksPharmaceutical Preparations Industry512th out of 685 stocksAnalyst Opinion: 0.9Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 0.9 Analyst's Opinion Consensus RatingRadius Health has received a consensus rating of Hold. The company's average rating score is 1.80, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.60, Radius Health has a forecasted downside of 16.4% from its current price of $10.29.Amount of Analyst CoverageRadius Health has only been the subject of 3 research reports in the past 90 days. Previous Next 4.5 Community Rank Outperform VotesRadius Health has received 512 “outperform” votes. (Add your “outperform” vote.)Underperform VotesRadius Health has received 231 “underperform” votes. (Add your “underperform” vote.)Community SentimentRadius Health has received 68.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote “Outperform” if you believe RDUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldRadius Health does not currently pay a dividend.Dividend GrowthRadius Health does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Radius Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,661,480.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.73% of the stock of Radius Health is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Radius Health are expected to grow in the coming year, from ($0.19) to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Radius Health is -6.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Radius Health is -6.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Radius Health (NASDAQ:RDUS)Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.Read More RDUS Stock News HeadlinesJune 28, 2022 | markets.businessinsider.comShort Volatility Alert: Radius Health, Inc.June 28, 2022 | benzinga.comEquity Alert - The M&A Class Action Firm Announces an Investigation of Radius Health, Inc. - RDUSJune 27, 2022 | apnews.comINVESTIGATION NOTICE: Halper Sadeh LLP Investigates RDUS, FSTX, ZEN, USAKJune 27, 2022 | americanbankingnews.comRadius Health (NASDAQ:RDUS) Price Target Raised to $10.00June 25, 2022 | americanbankingnews.comRadius Health (NASDAQ:RDUS) Sees Large Volume IncreaseJune 25, 2022 | benzinga.comRADIUS HEALTH ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of RDUS and Encourages Investors to Contact the FirmJune 24, 2022 | seekingalpha.comHot Stocks: KMX, BB rise on earnings; WOLF upgrade; RDUS slips after previous day's gainsJune 24, 2022 | bizjournals.comEquity firms to take Radius Health private for $890MJune 24, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Radius HealthJune 23, 2022 | apnews.comRDUS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Radius Health, Inc. Is Fair to ShareholdersJune 23, 2022 | marketwatch.comRadius Health Shares Leap on Deal to Be Taken Private >RDUSJune 23, 2022 | seekingalpha.comRadius Health jumps 14% on $890M buyout offerJune 23, 2022 | finance.yahoo.comBone Health Focused Radius Health Goes Private In $890M DealSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDUS CUSIPN/A CIK1428522 Webwww.radiuspharm.com Phone(617) 551-4000Fax617-551-4701Employees293Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today6/29/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$8.60 High Stock Price Forecast$10.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside-17.6%Consensus RatingHold Rating Score (0-4)1.8 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.540010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70.18 million Net Margins-33.52% Pretax Margin-33.52% Return on EquityN/A Return on Assets-40.69% Debt Debt-to-Equity RatioN/A Current Ratio1.81 Quick Ratio1.65 Sales & Book Value Annual Sales$229.97 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value($5.33) per share Price / Book-1.96Miscellaneous Outstanding Shares47,600,000Free Float46,777,000Market Cap$496.94 million OptionableOptionable Beta1.03 Radius Health Frequently Asked Questions Should I buy or sell Radius Health stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Radius Health stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares. View analyst ratings for Radius Health or view top-rated stocks. What is Radius Health's stock price forecast for 2022? 5 equities research analysts have issued 1 year target prices for Radius Health's stock. Their RDUS stock forecasts range from $7.00 to $10.00. On average, they predict Radius Health's stock price to reach $8.60 in the next year. This suggests that the stock has a possible downside of 17.6%. View analysts' price targets for Radius Health or view top-rated stocks among Wall Street analysts. How has Radius Health's stock performed in 2022? Radius Health's stock was trading at $6.92 on January 1st, 2022. Since then, RDUS shares have increased by 50.9% and is now trading at $10.44. View the best growth stocks for 2022 here. When is Radius Health's next earnings date? Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Radius Health. How were Radius Health's earnings last quarter? Radius Health, Inc. (NASDAQ:RDUS) announced its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.18. The biopharmaceutical company had revenue of $43.16 million for the quarter, compared to analysts' expectations of $51.42 million. During the same quarter in the previous year, the business earned ($0.34) earnings per share. View Radius Health's earnings history. Who are Radius Health's key executives? Radius Health's management team includes the following people: Mr. G. Kelly Martin, CEO, Pres & Director (Age 63, Pay $600.48k)Ms. Danielle Holtschlag, VP of Sales & Head of U.S. Sales Channels (Age 44, Pay $299.3k)Ms. Chhaya Shah, Sr. VP & Chief Bus. Officer (Age 58, Pay $631.62k)Dr. Stavros C. Manolagas, Founder & Member of the Scientific Advisory BoardDr. John Thomas Potts Jr., DSc, M.D., Founder & Member of the Scientific Advisory Board (Age 90)Dr. Michael Rosenblatt M.D., Founder, Board Observer & Member of Scientific Advisory Board (Age 74)Dr. John A. Katzenellenbogen, Founder & Member of the Scientific Advisory BoardMr. Mark William Conley CPA, VP, CFO, Principal Accounting Officer & Treasurer (Age 60)Mr. Peter A. Schwartzman, Head of Corp. Fin.Ethan Holdaway, Head of Investor Relations Who are some of Radius Health's key competitors? Some companies that are related to Radius Health include Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), Arcus Biosciences (RCUS), OPKO Health (OPK), Lyell Immunopharma (LYEL), Amphastar Pharmaceuticals (AMPH), Xenon Pharmaceuticals (XENE), Xencor (XNCR), Dynavax Technologies (DVAX), Emergent BioSolutions (EBS), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN) and Cryoport (CYRX). View all of RDUS's competitors. What other stocks do shareholders of Radius Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX). What is Radius Health's stock symbol? Radius Health trades on the NASDAQ under the ticker symbol "RDUS." Who are Radius Health's major shareholders? Radius Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bellevue Group AG (17.49%), State Street Corp (8.11%), Vanguard Group Inc. (7.65%), BlackRock Inc. (7.48%), Velan Capital Investment Management LP (2.99%) and UBS Group AG (2.83%). Company insiders that own Radius Health stock include Anthony Rosenberg, Growth N V Biotech, James George Chopas, Rubric Capital Management Lp and Target N V Biotech. View institutional ownership trends for Radius Health. Which major investors are selling Radius Health stock? RDUS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wellington Management Group LLP, UBS Group AG, State Street Corp, Bank of New York Mellon Corp, Walleye Capital LLC, Walleye Capital LLC, and Bank of America Corp DE. View insider buying and selling activity for Radius Health or view top insider-selling stocks. Which major investors are buying Radius Health stock? RDUS stock was bought by a variety of institutional investors in the last quarter, including Velan Capital Investment Management LP, Bellevue Group AG, Acadian Asset Management LLC, Eversept Partners LP, JPMorgan Chase & Co., Assenagon Asset Management S.A., BNP Paribas Arbitrage SA, and Pinz Capital Management LP. Company insiders that have bought Radius Health stock in the last two years include Rubric Capital Management Lp, and Target N V Biotech. View insider buying and selling activity for Radius Health or or view top insider-buying stocks. How do I buy shares of Radius Health? Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Radius Health's stock price today? One share of RDUS stock can currently be purchased for approximately $10.44. How much money does Radius Health make? Radius Health (NASDAQ:RDUS) has a market capitalization of $496.94 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70.18 million in net income (profit) each year or ($1.540010) on an earnings per share basis. How many employees does Radius Health have? Radius Health employs 293 workers across the globe. How can I contact Radius Health? Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for Radius Health is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at [email protected], or via fax at 617-551-4701. This page (NASDAQ:RDUS) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here